

## Clark &amp; Elbing LLP

101 Federal Street  
Boston, MA 02110Telephone 617-428-0200  
Facsimile 617-428-7045  
617-428-7046**Date:** June 13, 2005**To:** Examiner Kasbar**Facsimile No:** 571-273-0769**From:** Michael J. Belliveau**Re:** U.S. Patent Application Serial No. 10/600,272**Pages:** 4**Message:** Per our telephone conversation of last week, enclosed please find a proposed claim amendment in connection with the above-referenced case.

---

NOTICE: This facsimile transmission may contain confidential or privileged information intended for the addressee only. If you are not the addressee, be aware that any disclosure, copying, distribution, or use of the information is prohibited. If you have received this facsimile transmission in error, please call us at 617-428-0200 to arrange for its return at no cost to you.

---

U.S. Patent Application Serial No. 10/600,272  
Filed June 20, 2003

Robert G. Korneluk, Alexander E. MacKenzie, Stephen Baird, Peter Liston  
MAMMALIAN IAP GENE FAMILY, PRIMERS, PROBES  
AND DETECTION METHODS  
Our Reference: 07891/003006

\* Proposed claim amendments \*

1. (Currently amended) A substantially pure polypeptide consisting of a sequence having at least 95% sequence identity to SEQ ID NO: 24 or SEQ ID NO: 25 a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.
2. (Original) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 24.
3. (Original) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 25.
4. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 26.
5. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to SEQ ID NO: 27.
6. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at least 95% sequence identity to amino acids 255-322 of SEQ ID NO: 40.
7. (Cancelled) The polypeptide of claim 1, wherein said polypeptide has at

Attachment to Interview Summary (Not claim)

USSN 10/600,272  
Atty Docket: 07891/003006

2.

least 95% sequence identity to amino acids 241-308 of SEQ ID NO: 42.

8. (Currently amended) A substantially pure polypeptide consisting of SEQ ID NO: 24 or SEQ ID NO: 25 a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.

9. (Original) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 24.

10. (Original) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 25.

11. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 26.

12. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of SEQ ID NO: 27.

13. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the sequence of amino acids 255-322 of SEQ ID NO: 40.

14. (Cancelled) The polypeptide of claim 8, wherein said polypeptide has the

*Attachment to Review Summary (Not claim)*

USSN 10/600,272  
Atty Docket: 07891/003006

3.

sequence of amino acids 241-308 of SEQ ID NO: 42.

15. (Currently amended) A substantially pure polypeptide comprising SEQ ID NO: 24 or SEQ ID NO: 25 ~~a sequence selected from the group consisting of SEQ ID NOs: 24, 25, 26, and 27, amino acids 255-322 of SEQ ID NO: 40, and amino acids 241-308 of SEQ ID NO: 42~~, wherein said polypeptide is capable of inhibiting apoptosis of a mammalian cell when said polypeptide is expressed in said cell.

16. (Original) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 24.

17. (Original) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 25.

18. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 26.

19. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of SEQ ID NO: 27.

20. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of amino acids 255-322 of SEQ ID NO: 40.

21. (Cancelled) The polypeptide of claim 15, wherein said polypeptide comprises the sequence of amino acids 241-308 of SEQ ID NO: 42.

Attachment to Interview Summary (Not claims)